On the contrary, the data suggest a potential protective effect against the development of specific psychiatric disorders, and GLP-1s are actively being investigated for their potential role in the treatment of depression
In all cases, IGF-1 DES is more potent in stimulating these changes than IGF-1, indicating that the peptide might be an effective adjuvant to antibiotics and other treatments used in the setting of infectious disease
CJC-1295: Some studies have suggested that CJC-1295 may increase the risk of headache, gastrointestinal disturbances, and vasodilation symptoms, including facial flushing, sensations of warmth, and temporarily lowered blood pressure
Designing a Fat Loss Peptide Protocol: Stacking, Timing, and Safety Combining peptides requires a deep understanding of their mechanisms and potential interactions
This corresponds to an increase of ~225% of plasma glucagon when corrected for the change in glucose concentration
Month 7 through month 12: long-term transformation and maintenance The second half of the first year on GLP-1 therapy is where the transformation matures
